While theyre fundamentally similar medications, they differ slightly in their mechanism of action: Wegovy (semaglutide) is a GLP-1 agonist Zepbound (tirzepatide) is a dual agonist: GLP-1 + a glucose-dependent insulinotropic polypeptide (GIP) Both semaglutide and tirzepatide affect the hypothalamus and the hedonic eating centers, the brains center of appetite and cravings
These highlights do not include all the information needed to use WEGOVY Manufacturer Novo Nordisk Pharmaceutical Industries, LP | Novo Nordisk A/S - 25a-B Effective date 2026-06-18 Label type HUMAN PRESCRIPTION DRUG LABEL Version 19 Source monthly-update Hydrated at 2026-07-17 21:41:15 Label at a glance# Product WEGOVY Active ingredient SEMAGLUTIDE Label structure 37 sections Boxed warning In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
A 0.3 mL (30-unit) syringe with single-unit markings gives the best precision at this concentration
We selected only male rats, based on findings from previous research indicating that male mice showed a stronger response to cardiac pressure overload in terms of LVH development 40
Hiroaki Kimura, and Dr
There is a frequent coexistence of obesity and heart failure (HF), with more than half of patients participating in recent HF trials having a body mass index (BMI) of 30 kg/m 2 or above [1]